About this Event
Start-up companies usually have start-up boards — people elected by the Founder. What are the advantages and disadvantages?
Is this a good practice for the long run? Is there a point where “founder syndrome” inhibits independent thinking? And, how does a founder Board transition to a more independent diverse board?
About the speaker – Charlotte Sibley
Charlotte Sibley was in the executive leadership team of Shire plc (now Takeda) as Senior Vice President immediately prior to her Board service.
At Shire, Charlotte was in charge of global talent management and led strategic corporate and marketing initiatives. She is highly regarded for her strategic vision and excellence in building and leading teams.
Charlotte has built and led integrated commercial assessment and insights teams (market research, competitive intelligence, strategic forecasting, commercial evaluation, and decision science) spanning all sectors of the life sciences industry at J&J, BMS, Pharmacia/Pfizer, Millennium Pharmaceuticals/Takeda and Shire/Takeda.
She serves on the Board of Advicenne, S.A. (Euronext: ADVIC), a specialty pharmaceutical company focused on the treatment of renal disease, where she is a member of the Remuneration and CEO Search Committees. She previously served the boards of Taconic Biosciences, Inc., where she chaired the Nom/Gov Committee and served on the Compensation Committee, and American Pacific Corporation (NASDAQ: AMPAC), a leading custom manufacturer of pharmaceutical ingredients (APIs). She is an NACD Board Governance and Leadership Fellow.
Charlotte has received numerous awards for leadership and achievement, including Middlebury College’s Alumni Achievement Award in 2018, and the Healthcare Businesswomen’s Association (HBA) 2008 Woman of the Year, recognizing her industry leadership, business expertise, and mentoring.
MBA, University of Chicago; AB, Middlebury College.